Johnson & Johnson’s (NYSE:JNJ) product recalls, litigation and patent battles have taken a toll on the company’s profits in the fourth quarter of 2011.The medical device and pharmaceutical giant, based in New Brunswick, New Jersey, reported one-time charges of $3 billion that include settlements associated with off-marketing allegations over its anti-psychotic drug Risperdal and recalls [...]

Johnson & Johnson (NYSE:JNJ) is poised to pay more than $1 billion to the federal government and several states as part of an agreement to end a civil investigation over its marketing of antipsychotic drug Risperdal, according to a report by Bloomberg.The New Brunswick, New Jersey company reached the deal with the U.S. attorney in [...]

Johnson & Johnson (NYSE: JNJ) has issued its latest recall of Motrin, this time from retailers over slow-working tablets and caplets, bringing the number of recalls for this drug alone to six in the past two years, and calling attention to the manufacturing woes faced by the drug maker.J&J subsidiary McNeil’s consumer division recalled 12 [...]

The sentencing of three of the four ex-directors of medical device manufacturer Synthes to terms ranging from five to nine months over the unauthorized use of bone cement in spinal surgery clinical trials in the case United States. v. Norian crisscrosses between regulatory issues and corporate responsibility.Synthes subsidiary Norian conducted a clinical trial using its [...]

The Food and Drug Administration has approved Bayer and J& J (NYSE: JNJ) drug Xarelto to treat atrial fibrillation, or abnormal heart rhythm.Earlier this year, Xarelto was approved for use as an anti-coagulant following knee or hip replacement surgery.In September scientists at the FDA recommended that the regulatory agency restrict use of the companies’ blood [...]

Surgical products company Ethicon Endo-Surgery, a division of Johnson & Johnson (NYSE:JNJ), is entering the medical device reprocessing and remanufacturing business with a planned acquisition of SterilMed.The price of the deal isn’t being disclosed, according to a statement from Cincinnati-based Ethicon.With the cost of healthcare in the U.S. continuing to skyrocket, medical device reprocessing could [...]

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com.Now here’s the best of what YOU had to say:End of J&J stent business carries lessons for medical device innovators. “Last week’s news that J&J is abandoning their coronary stent business was [...]

Cordis Corp., one of the most powerful players in coronary stents and the first to bring a drug-eluting stent to market is getting out of the business. The Johnson & Johnson (NYSE:JNJ) subsidiary, announced Wednesday morning that it will drop its stent business entirely, including work on novel DES designs.Since news of the [...]

Johnson & Johnson (NYSE:JNJ) is in talks to buy Synthes Inc. for $20 billion, according to a report in the Wall Street Journal.The Journal, citing anonymous sources with knowledge of the situation, reported late Friday that the New Brunswick, N.J.-based conglomerate had made an overture to buy the Swiss medical device giant in [...]

Johnson & Johnson (NYSE:JNJ) saved millions in criminal fines for providing federal prosecutors with information on its competitors’ transgressions, according to a U.S. Dept. of Justice press release.The medical products conglomerate received “a reduction in its criminal fine as a result of its cooperation in the ongoing investigation of other [...]